Elotuzumab: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Elotuzumab, so there is currently no new predicted indication. The drug’s own recorded uses are listed below.
Quick overview
Item
Content
New predicted indications
None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug
2
Evidence level
Not applicable
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
multiple myeloma
licence in another country
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
plasma cell myeloma
Australia Market Information
Licence
Product
Dosage form
Status
12983H
Empliciti
Powder for injection 300 mg
Valid
Safety Considerations
Drug Interactions: The interaction screen returned 100 potential interactions. Most are Moderate severity. Two Major interactions appear in the listed entries:
Samarium (153Sm) lexidronam (Major)
Adalimumab (Major)
Examples of Moderate interactions include naltrexone, metronidazole, rosuvastatin, simvastatin, tinidazole, chloroquine, hydroxychloroquine, disulfiram, paclitaxel and zidovudine. Only 20 of the 100 interactions were available for review, and the clinical significance of each should be checked against the full interaction record.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.